1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Durect dives on Posidur rejection

 
• By Donna Young

Shares of Durect plummeted 30% in after-hours trading on 12 February after the company revealed it had received a complete response letter (CRL) from the FDA for the drug maker’s post-operative pain relief product Posidur, which uses the firm’s Saber technology to deliver bupivacaine.

Shares of Durect plummeted 30% in after-hours trading on 12 February after the company revealed it had received a complete response letter (CRL) from the FDA for the drug maker’s post-operative pain relief product Posidur, which uses the firm’s Saber technology to deliver bupivacaine.

The FDA told Durect that its new drug application failed to contain sufficient information to demonstrate that Posidur is safe...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.